Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges

Total Page:16

File Type:pdf, Size:1020Kb

Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges PERSPECTIVE JBMR Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges Michael P Whyte Department of Internal Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, and Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St. Louis, MO, USA ABSTRACT Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Autosomal inheritance (dominant or recessive) from among more than 300 predominantly missense defects of TNSALP (ALPL) explains HPP’s broad-ranging severity, the greatest of all skeletal diseases. In health, TNSALP is linked to cell surfaces and richly expressed in the skeleton and developing teeth. In HPP,TNSALP substrates accumulate extracellularly, including inorganic pyrophosphate (PPi), an inhibitor of mineralization. The PPi excess can cause tooth loss, rickets or osteomalacia, calcific arthropathies, and perhaps muscle weakness. Severely affected infants may seize from insufficient hydrolysis of pyridoxal 5‘- phosphate (PLP), the major extracellular vitamin B6. Now, significant successes are documented for newborns, infants, and children severely affected by HPP given asfotase alfa, a hydroxyapatite-targeted recombinant TNSALP. Since fall 2015, this biologic is approved by regulatory agencies multinationally typically for pediatric-onset HPP. Safe and effective treatment is now possible for this last rickets to have a medical therapy, but a number of challenges involving diagnosis, understanding prognosis, and providing this treatment are reviewed herein. © 2017 American Society for Bone and Mineral Research. KEY WORDS: ALKALINE PHOSPHATASE; CALCIFICATION; CHONDROCALCINOSIS; HYDROXYAPATITE; HYPERCALCEMIA; INBORN-ERROR-OF- METABOLISM; INORGANIC PYROPHOSPHATE; MATRIX VESICLE; MINERALIZATION; OSTEOMALACIA; RICKETS; VITAMIN B6 Introduction phosphohydrolase activity leads to extracellular accumulation of its natural substrates,(3,4) including inorganic pyrophosphate (9) n fall 2015, our field achieved a milestone in the management (PPi), a potent inhibitor of hydroxyapatite (HA) crystal (10) Iof rickets and osteomalacia. Among the disorders that feature formation and propagation. Mineralization that should occur, generalized impairment of hard tissue mineralization and its including after rupture of matrix vesicles (MVs) containing consequences,(1) the final entity lacking a medical treatment nascent HA crystals, is instead blocked by the superabundance (11) acquired one sanctioned internationally by regulatory agencies. of extracellular PPi (ePPi). Consequently, patients suffer (5,6) The holdout was hypophosphatasia (HPP), the inborn-error-of- dental disease and a distinctive rickets or osteomalacia. In metabolism identified in 1948(2) and caused by loss-of-function severely affected neonates and infants, insufficient dephos- 0 mutation(s) of the TNSALP (ALPL) gene that encodes the “tissue- phorylation of pyridoxal 5 -phosphate (PLP), the major circulat- (3,4) nonspecific” isoenzyme of alkaline phosphatase (TNSALP). ing form of vitamin B6, can compromise neurotransmitter (12) The therapy is asfotase alfa (AA), a recombinant bone-targeted synthesis in the brain and cause epilepsy. Reports now ALP now typically approved for pediatric-onset HPP.(5–7) This totaling several hundred HPP patients have delineated the advance ended hopelessness for many HPP patients and offers disorder’s key clinical and biochemical features and its physicians important successes in treating an orphan disease. radiographic and histopathological findings in the skeleton. However, as I will discuss, a number of challenges call for further The genetic basis is established, and its pathophysiology is (3,4,8) progress and an especially thorough understanding of HPP, largely understood. The extraordinarily broad expressivity particularly its wide-ranging severity.(3,4) Reviews concerning of HPP is known to span at one extreme death in utero due to an HPP,(3,4,8) including comprehensive reports from testing this unmineralized skeleton, and at the other extreme dental biologic in pediatric patients,(5–7) have been published recently. complications or arthropathy without bone disease presenting in middle age or later.(3,4,13) I see HPP’s range of severity as Background greatest among all skeletal diseases.(3) Life-threatening HPP reflects autosomal recessive inheritance(14,15) and occurs in 1 TNSALP (liver/bone/kidney ALP) is found on cell surfaces, richly per 100,000 and 300,000 births in Canada(16) and in Europe,(17) in the skeleton and developing teeth.(8) In HPP, deficient TNSALP respectively. For Mennonites in Manitoba, Canada, 1in25 Received in original form November 4, 2016; revised form December 9, 2016; accepted December 26, 2016. Accepted manuscript online January 13, 2017. Address correspondence to: Dr. Michael P Whyte, MD, Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, 4400 Clayton Avenue, St. Louis, MO 63110, USA. E-mail: [email protected] Additional Supporting Information may be found in the online version of this article. Journal of Bone and Mineral Research, Vol. 32, No. 4, April 2017, pp 667–675 DOI: 10.1002/jbmr.3075 © 2017 American Society for Bone and Mineral Research 667 individuals carries a TNSALP founder mutation, and 1 in 2500 (Fig. 2A) and bone biopsy show no abnormalities, and health is newborns manifests perinatal HPP.(18) Two TNSALP founder otherwise good (Supplemental Video S1). mutations underlie severe HPP in the Japanese.(19) In the United Adult HPP typically presents in middle age,(26–28) yet some States, white ancestry seems disproportionately predominant patients recount early shedding of deciduous teeth or past for HPP,(14,20) and two prevalent TNSALP missense defects rickets.(3,4) Loss of secondary dentition seems common.(26) Then, explain relatively many occurrences from autosomal dominant recurrent metatarsal stress fractures beginning in adult life inheritance.(21,22) TNSALP mutation analysis has suggested eventually fail to heal.(26–28) Subsequently, hip or thigh pain may “moderately” severe HPP affects 1 in 6370 Europeans.(17) HPP indicate femoral pseudofractures,(29) a radiographic hallmark of carrier prevalence in the United States and in Europe (E Mornet, osteomalacia resembling the prodromal lesion of atypical personal communication) might be 1 per 250 to 300 people. subtrochanteric femoral fractures associated with bone anti- resorptive treatment (Fig. 3).(30) Excessive ePPi can also cause HPP Nosology calcium pyrophosphate dihydrate crystal deposition (chondro- calcinosis) and PPi arthropathy including pseudogout.(31,32) Beginning in 1957,(16) a clinical nosology for HPP evolved that Seemingly paradoxical in HPP, calcific periarthritis is deposition helps organize its remarkable range of severity that is largely of HA near joints(13) and syndesmophytes can cause ankylosing explained by autosomal recessive or autosomal dominant spinal hyperostosis (Forestier disease).(31) Recurrent fracturing, transmission from among at least 310 mutations (typically skeletal and joint pain, and muscle weakness sometimes missense) scattered throughout TNSALP (ALPL).(15) This nosol- become debilitating.(33) ogy emphasizes whether only dental manifestations are Childhood HPP presents during growth after age 6 months. present, or patient age when skeletal or other significant Premature exfoliation of one or more primary teeth is nearly complications have emerged.(3,4) Now, seven major forms of inevitable,(14,20) and sometimes all are lost early.(14) Health is HPP guide recurrence risk prediction, prognostication, and generally good in mild childhood HPP (Supplemental Video S2), research.(23–25) Dental issues alone denote “odonto” HPP, the with only subtle bone changes disclosed radiographically mildest and likely most common HPP. Then, ranked by (Fig. 2B). In contrast, severe childhood HPP substantially increasing severity with younger age at presentation and compromises health (Supplemental Video S3) and skeletal perhaps diminishing prevalence, clinicians can encounter pain and muscle weakness can be significant. These patients can “adult” HPP, “mild childhood” HPP, “severe childhood” HPP, have a misshapen skull, bowed legs or knock knees, and “infantile” HPP, and “perinatal” HPP.(3,4) Finally, “benign enlarged “joints” from metaphyseal flaring. Muscle weakness prenatal” HPP refers to the newborn with skeletal abnormali- helps explain their delayed walking and waddling gait.(6,34) ties in utero or at birth from HPP that improve spontaneously Craniosynostosis can raise intracranial pressure and damage the during late pregnancy and ex utero.(23) I refer to the many brain. Radiographs of major long bones reveal characteristic people who harbor one TNSALP mutation yet have good “tongues” of lucency projecting from growth plates into health as “carriers” of HPP (see Challenges). These principal metaphyses where there is patchy osteosclerosis and osteope- forms of HPP are described briefly below. nia (Fig. 2C).(3–6) Physes can be wide and irregular and Odonto HPP refers to dental complications of HPP at any age metaphyses flared. Dental pulp chambers and root canals but without other physical or radiographic signs of the disease. may be large and resemble “shell teeth.” Nevertheless, HPP in Painless premature (ie, age <5 years) loss of one or more children is typically a stable condition.(25) In
Recommended publications
  • Hypophosphatasia Could Explain Some Atypical Femur Fractures
    Hypophosphatasia Could Explain Some Atypical Femur Fractures What we know Hypophosphatasia (HPP) is a rare genetic disease that affects the development of bones and teeth in children (Whyte 1985). HPP is caused by the absence or reduced amount of an enzyme called tissue-nonspecific alkaline phosphatase (TAP), also called bone-specific alkaline phosphatase (BSAP). The absence of TAP raises the level of inorganic pyrophosphate (Pi), which prevents calcium and phosphate from creating strong, mineralized bone. Without TAP, bones can become weak. In its severe form, HPP is fatal and happens in 1/100,000 births. Because HPP is genetic, it can appear in adults as well. A recent study has identified a milder, more common form of HPP that occurs in 4 of 1000 adults (Dahir 2018). This form of HPP is usually seen in early middle aged adults who have low bone density and sometimes have stress fractures in the feet or thigh bone. Sometimes these patients lose their baby teeth early, but not always. HPP is diagnosed by measuring blood levels of TAP and vitamin B6. An elevated vitamin B6 level [serum pyridoxal 5-phosphate (PLP)] (Whyte 1985) in a patient with a TAP level ≤40 or in the low end of normal can be diagnosed with HPP. Almost half of the adult patients with HPP in the large study had TAP >40, but in the lower end of the normal range (Dahir 2018). The connection between hypophosphatasia and osteoporosis Some people who have stress fractures get a bone density test and are treated with an osteoporosis medicine if their bone density results are low.
    [Show full text]
  • Diagnosis and Treatment of Intramedullary Osteosclerosis
    Abe et al. BMC Musculoskeletal Disorders (2020) 21:762 https://doi.org/10.1186/s12891-020-03758-5 CASE REPORT Open Access Diagnosis and treatment of intramedullary osteosclerosis: a report of three cases and literature review Kensaku Abe, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi* , Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Yuta Taniguchi, Hirotaka Yonezawa, Yoshihiro Araki, Sei Morinaga, Yohei Asano and Hiroyuki Tsuchiya Abstract Background: Intramedullary osteosclerosis (IMOS) is a rare condition without specific radiological findings except for the osteosclerotic lesion and is not associated with family history and infection, trauma, or systemic illness. Although the diagnosis of IMOS is confirmed after excluding other osteosclerotic lesions, IMOS is not well known because of its rarity and no specific feature. Therefore, these situations might result in delayed diagnosis. Hence, this case report aimed to investigate three cases of IMOS and discuss imaging findings and clinical outcomes. Case presentation: All three cases were examined between 2015 and 2019. The location of osteosclerotic lesions were femoral diaphyses in the 60-year-old man (Case 1) and 41-year-old woman (Case 2) and tibial diaphysis in the 44-year-old woman (Case 3). All cases complained of severe pain and showed massive diaphyseal osteosclerotic lesions in plain radiograms and computed tomography (CT) scans. Cases 2 and 3 were examined using the triphasic bone scan, and a fusiform-shaped intense area of the tracer uptake on delayed bone image was detected in both cases without (Case 2) or slightly increased vascularity (Case 3) on the blood pool image, which was reported as a specific finding of IMOS.
    [Show full text]
  • Establishment of a Dental Effects of Hypophosphatasia Registry Thesis
    Establishment of a Dental Effects of Hypophosphatasia Registry Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Jennifer Laura Winslow, DMD Graduate Program in Dentistry The Ohio State University 2018 Thesis Committee Ann Griffen, DDS, MS, Advisor Sasigarn Bowden, MD Brian Foster, PhD Copyrighted by Jennifer Laura Winslow, D.M.D. 2018 Abstract Purpose: Hypophosphatasia (HPP) is a metabolic disease that affects development of mineralized tissues including the dentition. Early loss of primary teeth is a nearly universal finding, and although problems in the permanent dentition have been reported, findings have not been described in detail. In addition, enzyme replacement therapy is now available, but very little is known about its effects on the dentition. HPP is rare and few dental providers see many cases, so a registry is needed to collect an adequate sample to represent the range of manifestations and the dental effects of enzyme replacement therapy. Devising a way to recruit patients nationally while still meeting the IRB requirements for human subjects research presented multiple challenges. Methods: A way to recruit patients nationally while still meeting the local IRB requirements for human subjects research was devised in collaboration with our Office of Human Research. The solution included pathways for obtaining consent and transferring protected information, and required that the clinician providing the clinical data refer the patient to the study and interact with study personnel only after the patient has given permission. Data forms and a custom database application were developed. Results: The registry is established and has been successfully piloted with 2 participants, and we are now initiating wider recruitment.
    [Show full text]
  • Metabolic Bone Disease 5
    g Metabolic Bone Disease 5 Introduction, 272 History and examination, 275 Osteoporosis, 283 STRUCTURE AND FUNCTION, 272 Investigation, 276 Paget’s disease of bone, 288 Structure of bone, 272 Management, 279 Hyperparathyroidism, 290 Function of bone, 272 DISEASES AND THEIR MANAGEMENT, 280 Hypercalcaemia of malignancy, 293 APPROACH TO THE PATIENT, 275 Rickets and osteomalacia, 280 Hypocalcaemia, 295 Introduction Calcium- and phosphate-containing crystals: set in a structure• similar to hydroxyapatite and deposited in holes Metabolic bone diseases are a heterogeneous group of between adjacent collagen fibrils, which provide rigidity. disorders characterized by abnormalities in calcium At least 11 non-collagenous matrix proteins (e.g. osteo- metabolism and/or bone cell physiology. They lead to an calcin,• osteonectin): these form the ground substance altered serum calcium concentration and/or skeletal fail- and include glycoproteins and proteoglycans. Their exact ure. The most common type of metabolic bone disease in function is not yet defined, but they are thought to be developed countries is osteoporosis. Because osteoporosis involved in calcification. is essentially a disease of the elderly, the prevalence of this condition is increasing as the average age of people Cellular constituents in developed countries rises. Osteoporotic fractures may lead to loss of independence in the elderly and is imposing Mesenchymal-derived osteoblast lineage: consist of an ever-increasing social and economic burden on society. osteoblasts,• osteocytes and bone-lining cells. Osteoblasts Other pathological processes that affect the skeleton, some synthesize organic matrix in the production of new bone. of which are also relatively common, are summarized in Osteoclasts: derived from haemopoietic precursors, Table 3.20 (see Chapter 4).
    [Show full text]
  • Periapical Radiopacities
    2016 self-study course two course The Ohio State University College of Dentistry is a recognized provider for ADA CERP credit. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at www.ada.org/cerp. The Ohio State University College of Dentistry is approved by the Ohio State Dental Board as a permanent sponsor of continuing dental education. This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint efforts between The Ohio State University College of Dentistry Office of Continuing Dental Education and the Sterilization Monitoring Service (SMS). ABOUT this COURSE… FREQUENTLY asked QUESTIONS… . READ the MATERIALS. Read and Q: Who can earn FREE CE credits? review the course materials. COMPLETE the TEST. Answer the A: EVERYONE - All dental professionals eight question test. A total of 6/8 in your office may earn free CE questions must be answered correctly credits. Each person must read the contact for credit. course materials and submit an online answer form independently. SUBMIT the ANSWER FORM ONLINE. You MUST submit your answers ONLINE at: Q: What if I did not receive a confirmation ID? us http://dentistry.osu.edu/sms-continuing-education A: Once you have fully completed your .
    [Show full text]
  • Hematological Diseases and Osteoporosis
    International Journal of Molecular Sciences Review Hematological Diseases and Osteoporosis , Agostino Gaudio * y , Anastasia Xourafa, Rosario Rapisarda, Luca Zanoli , Salvatore Santo Signorelli and Pietro Castellino Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; [email protected] (A.X.); [email protected] (R.R.); [email protected] (L.Z.); [email protected] (S.S.S.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +39-095-3781842; Fax: +39-095-378-2376 Current address: UO di Medicina Interna, Policlinico “G. Rodolico”, Via S. Sofia 78, 95123 Catania, Italy. y Received: 29 April 2020; Accepted: 14 May 2020; Published: 16 May 2020 Abstract: Secondary osteoporosis is a common clinical problem faced by bone specialists, with a higher frequency in men than in women. One of several causes of secondary osteoporosis is hematological disease. There are numerous hematological diseases that can have a deleterious impact on bone health. In the literature, there is an abundance of evidence of bone involvement in patients affected by multiple myeloma, systemic mastocytosis, thalassemia, and hemophilia; some skeletal disorders are also reported in sickle cell disease. Recently, monoclonal gammopathy of undetermined significance appears to increase fracture risk, predominantly in male subjects. The pathogenetic mechanisms responsible for these bone loss effects have not yet been completely clarified. Many soluble factors, in particular cytokines that regulate bone metabolism, appear to play an important role. An integrated approach to these hematological diseases, with the help of a bone specialist, could reduce the bone fracture rate and improve the quality of life of these patients.
    [Show full text]
  • Molecular Characterization of Three Canine Models of Human Rare Bone Diseases: Caffey, Van Den Ende-Gupta, and Raine Syndromes
    RESEARCH ARTICLE Molecular Characterization of Three Canine Models of Human Rare Bone Diseases: Caffey, van den Ende-Gupta, and Raine Syndromes Marjo K. Hytönen1,2,3, Meharji Arumilli1,2,3, Anu K. Lappalainen4, Marta Owczarek-Lipska5, Vidhya Jagannathan5, Sruthi Hundi1,2,3, Elina Salmela1,2,3, Patrick Venta6, Eva Sarkiala4, Tarja Jokinen1,4, Daniela Gorgas7, Juha Kere2,3,8, Pekka Nieminen9, Cord Drögemüller5☯, a11111 Hannes Lohi1,2,3☯* 1 Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland, 2 Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland, 3 The Folkhälsan Institute of Genetics, Helsinki, Finland, 4 Department of Equine and Small Animal Medicine, University of Helsinki, Helsinki, Finland, 5 Institute of Genetics, Vetsuisse Faculty, University of Bern, Bern, Switzerland, 6 Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, United States of America, 7 Division of Clinical Radiology, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, OPEN ACCESS University of Bern, Bern, Switzerland, 8 Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden, 9 Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Citation: Hytönen MK, Arumilli M, Lappalainen AK, Finland Owczarek-Lipska M, Jagannathan V, Hundi S, et al. ☯ (2016) Molecular Characterization of Three Canine These authors contributed equally to this work. * [email protected] Models of Human Rare Bone Diseases: Caffey, van den Ende-Gupta, and Raine Syndromes. PLoS Genet 12(5): e1006037. doi:10.1371/journal. pgen.1006037 Abstract Editor: Leigh Anne Clark, Clemson University, UNITED STATES One to two percent of all children are born with a developmental disorder requiring pediatric hospital admissions.
    [Show full text]
  • Core Decompression for Avascular Necrosis (For North Carolina Only) – Community Plan Medical Policy
    UnitedHealthcare® Community Plan Medical Policy Core Decompression for Avascular Necrosis (for North Carolina Only) Policy Number: CSNCT0219.01 Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Related Policies Application.......................................................................................... 1 None Coverage Rationale ........................................................................... 1 Applicable Codes .............................................................................. 1 Description of Services ..................................................................... 2 Clinical Evidence ............................................................................... 3 U.S. Food and Drug Administration ................................................ 7 References ......................................................................................... 7 Policy History/Revision Information................................................ 8 Instructions for Use ........................................................................... 8 Application This Medical Policy only applies to the state of North Carolina. Coverage Rationale Core decompression is proven and medically necessary for treating early (pre-collapse stage I and II) avascular necrosis of the femoral head. Core decompression is unproven and not medically necessary for treating late avascular necrosis of the femoral head or for avascular necrosis elsewhere, including the humeral head, the distal femur, the talus, or the
    [Show full text]
  • Blueprint Genetics Comprehensive Skeletal Dysplasias and Disorders
    Comprehensive Skeletal Dysplasias and Disorders Panel Test code: MA3301 Is a 251 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of disorders involving the skeletal system. About Comprehensive Skeletal Dysplasias and Disorders This panel covers a broad spectrum of skeletal disorders including common and rare skeletal dysplasias (eg. achondroplasia, COL2A1 related dysplasias, diastrophic dysplasia, various types of spondylo-metaphyseal dysplasias), various ciliopathies with skeletal involvement (eg. short rib-polydactylies, asphyxiating thoracic dysplasia dysplasias and Ellis-van Creveld syndrome), various subtypes of osteogenesis imperfecta, campomelic dysplasia, slender bone dysplasias, dysplasias with multiple joint dislocations, chondrodysplasia punctata group of disorders, neonatal osteosclerotic dysplasias, osteopetrosis and related disorders, abnormal mineralization group of disorders (eg hypopohosphatasia), osteolysis group of disorders, disorders with disorganized development of skeletal components, overgrowth syndromes with skeletal involvement, craniosynostosis syndromes, dysostoses with predominant craniofacial involvement, dysostoses with predominant vertebral involvement, patellar dysostoses, brachydactylies, some disorders with limb hypoplasia-reduction defects, ectrodactyly with and without other manifestations, polydactyly-syndactyly-triphalangism group of disorders, and disorders with defects in joint formation and synostoses. Availability 4 weeks Gene Set Description
    [Show full text]
  • Sclerosing Bone Dysplasias: Genetic, Clinical and Radiology Update of Hereditary and Non-Hereditary Disorders
    BJR © 2016 The Authors. Published by the British Institute of Radiology Received: Revised: Accepted: http://dx.doi.org/10.1259/bjr.20150349 26 April 2015 14 December 2015 17 February 2016 Cite this article as: Boulet C, Madani H, Lenchik L, Vanhoenacker F, Amalnath DS, De Mey J, et al. Sclerosing bone dysplasias: genetic, clinical and radiology update of hereditary and non-hereditary disorders. Br J Radiol 2016; 89: 20150349. REVIEW ARTICLE Sclerosing bone dysplasias: genetic, clinical and radiology update of hereditary and non-hereditary disorders 1CEDRIC BOULET, MD, 2HARDI MADANI, FRCR, 3LEON LENCHIK, MD, 4FILIP VANHOENACKER, MD, PhD, 5DEEPAK S AMALNATH, MD, 1JOHAN DE MEY, MD, PhD and 1MICHEL DE MAESENEER, MD, PhD 1Department of Radiology, Universitair Ziekenhuis Brussel, Brussel, Belgium 2Department of Radiology, Royal Free Hospital, London, UK 3Department of Radiology, Wake Forest University, Winston Salem, NC, USA 4Department of Radiology, Universitair Ziekenhuis Anwerpen, Antwerpen, Belgium 5Department of Medicine, Indira Gandhi Medical College and Research Institute, Pondicherry, India Address correspondence to: Dr Michel De Maeseneer E-mail: [email protected] ABSTRACT There is a wide variety of hereditary and non-hereditary bone dysplasias, many with unique radiographic findings. Hereditary bony dysplasias include osteopoikilosis, osteopathia striata, osteopetrosis, progressive diaphyseal dysplasia, hereditary multiple diaphyseal sclerosis and pyknodysostosis. Non-hereditary dysplasias include melorheostosis, intramedullary osteosclerosis and overlap syndromes. Although many of these dysplasias are uncommon, radiologists should be familiar with their genetic, clinical and imaging findings to allow for differentiation from acquired causes of bony sclerosis. We present an overview of hereditary and non-hereditary bony dysplasias with focus on the pathogenesis, clinical and radiographic findings of each disorder.
    [Show full text]
  • Crystal Deposition in Hypophosphatasia: a Reappraisal
    Ann Rheum Dis: first published as 10.1136/ard.48.7.571 on 1 July 1989. Downloaded from Annals of the Rheumatic Diseases 1989; 48: 571-576 Crystal deposition in hypophosphatasia: a reappraisal ALEXIS J CHUCK,' MARTIN G PATTRICK,' EDITH HAMILTON,' ROBIN WILSON,2 AND MICHAEL DOHERTY' From the Departments of 'Rheumatology and 2Radiology, City Hospital, Nottingham SUMMARY Six subjects (three female, three male; age range 38-85 years) with adult onset hypophosphatasia are described. Three presented atypically with calcific periarthritis (due to apatite) in the absence of osteopenia; two had classical presentation with osteopenic fracture; and one was the asymptomatic father of one of the patients with calcific periarthritis. All three subjects over age 70 had isolated polyarticular chondrocalcinosis due to calcium pyrophosphate dihydrate crystal deposition; four of the six had spinal hyperostosis, extensive in two (Forestier's disease). The apparent paradoxical association of hypophosphatasia with calcific periarthritis and spinal hyperostosis is discussed in relation to the known effects of inorganic pyrophosphate on apatite crystal nucleation and growth. Hypophosphatasia is a rare inherited disorder char- PPi ionic product, predisposing to enhanced CPPD acterised by low serum levels of alkaline phos- crystal deposition in cartilage. copyright. phatase, raised urinary phosphoethanolamine Paradoxical presentation with calcific peri- excretion, and increased serum and urinary con- arthritis-that is, excess apatite, in three adults with centrations
    [Show full text]
  • Osteopetrosis Associated with Familial Paraplegia: Report of a Family
    Paraplegia (1975), 13, 143-152 OSTEOPETROSIS ASSOCIATED WITH FAMILIAL PARAPLEGIA: REPORT OF A FAMILY By SKIP JACQUES*, M.D., JOHN T. GARNER, M. D., DAVID JOHNSON, M.D. and C. HUNTER SHELDEN, M. D. Departments of Neurosurgery and Radiology, Huntington Memorial Hospital, Pasadena, Ca., and the Huntington Institute of Applied Medical Research, Pasadena, Ca., U.S.A. Abstract. A clinical analysis of three members of a family with documented osteopetrosis and familial paraplegia is presented. All patients had a long history of increased bone density and slowly progressing paraparesis of both legs. A thorough review of the literature has revealed no other cases which presented with paraplegia without spinal cord com­ pression. Although the etiologic factor or factors remain unknown, our review supports the contention that this is a distinct clinical entity. IN 1904, a German radiologist, Heinrich Albers-Schonberg, described a 26-year­ old man with multiple fractures and generalised sclerosis of the skeleton. The disease has henceforth commonly been known as Albers-Schonberg disease or marble osteopetrosis, a term first introduced by Karshner in 1922. Other eponyms are bone disease, osteosclerosis fragilis generalisata, and osteopetrosis generalisata. Approximately 300 cases had been reported in the literature by 1968. It has been generally accepted that the disease presents in two distinct forms, an infantile progressive disease and a milder form in childhood and adolescence. The two forms differ clinically and genetically. A dominant pattern of inheritance is usually seen in the benign type whereas the severe infantile form is usually inherited as a Mendelian recessive. This important distinction has not been well emphasised.
    [Show full text]